Mannan Mucin-1 Peptide Immunization: Influence of Cyclophosphamide and the Route of Injection

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of immunotherapy

• Publication date

  2001-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00002371-200103000-00012PMID 11265775
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy.

  2000cited by this paper
• Parameters for using mannan-MUC1 fusion protein to induce cellular immunity

  1998cited by this paper
• Cyclophosphamide Enhances the CTL Precursor Frequency in Mice Imrnunized with MUC1‐Mannan Fusion Protein (M‐FP)

  1998cited by this paper
• Anti-MUC1 antibodies react directly with MUC1 peptides presented by class I H2 and HLA molecules.

  1998cited by this paper
• Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation.

  1998cited by this paper
• MUC1 cross-reactive Galα(l,3)Gal antibodies in humans switch immune responses from cellular to humoral

  1998cited by this paper
• Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes

  1998cited by this paper
• The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy.

  1998cited by this paper
• Effect of route of immunisation and adjuvant on T and B cell epitope recognition within a streptococcal antigen.

  1998cited by this paper
• Anti‐MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide

  1998cited by this paper
• Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.

  1997cited by this paper
• Cell-mediated immune responses to MUC1 fusion protein coupled to mannan.

  1996cited by this paper
• A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer.

  1996cited by this paper
• Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine.

  1996cited by this paper
• A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma.

  1996cited by this paper
• Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses.

  1995cited by this paper
• Epithelial mucin genes.

  1995cited by this paper
• Phase-I study of synthetic muc1 peptides in breast-cancer.

  1995cited by this paper
• Immune modulating effects of low doses of cyclophosphamide and keyhole limpet hemocyanin on peripheral blood immune parameters in patients with metastatic renal cell carcinoma.

  1992cited by this paper
• Molecular aspects of mucins

  1988cited by this paper
• Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide.

  1986cited by this paper

• Development of Methamphetamine Conjugated Vaccine through Hapten Design: In Vitro and In Vivo Characterization

  2023cites this paper
• Immunomodulatory glycomedicine: Introducing next generation cancer glycovaccines.

  2023cites this paper
• The Mucin Family of Proteins: Candidates as Potential Biomarkers for Colon Cancer

  2023cites this paper
• Development and characterization of a novel conjugated methamphetamine vaccine.

  2022cites this paper
• Novel Approaches in the Immunotherapy of Multiple Sclerosis: Cyclization of Myelin Epitope Peptides and Conjugation with Mannan

  2021cites this paper
• Identification, annotation of Mucin genes in channel catfish(Ictalurus punctatus)and their expression after bacterial infections revealed by RNA‐Seq analysis

  2020cites this paper
• Carbohydrate Immune Adjuvants in Subunit Vaccines

  2020cites this paper
• The Use of Electrochemical Voltammetric Techniques and High-Pressure Liquid Chromatography to Evaluate Conjugation Efficiency of Multiple Sclerosis Peptide-Carrier Conjugates

  2020cites this paper
• Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer

  2020cites this paper
• The Long Road of Immunotherapeutics against Multiple Sclerosis †

  2020cites this paper
• Carbohydrate Conjugates in Vaccine Developments

  2020cites this paper
• Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens

  2018cites this paper
• Chimeric antigen receptor (CAR) T-cell immunotherapy for MUC1-positive breast cancer

  2018cites this paper
• Immune suppression and reversal of the suppressive tumor microenvironment

  2018cites this paper
• Vaccines for colorectal cancer: an update

  2018cites this paper
• Therapeutic cancer vaccines.

  2017cites this paper
• Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines

  2017cites this paper
• Mannosylated T/Tn with Freund’s adjuvant induces cellular immunity

  2017cites this paper
• Cancer Vaccines

  2017cites this paper
• Novel avenues in immunotherapies for colorectal cancer

  2016cites this paper
• T/Tn immunotherapy avoiding immune deviation

  2016cites this paper
• Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung

  2015cites this paper
• The potential role of immunotherapy to treat colorectal cancer

  2015cites this paper
• Update on Mucin-1 immunotherapy in cancer: a clinical perspective

  2015cites this paper
• Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.

  2015cites this paper
• Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies

  2015cites this paper
• Dendritic cell immunotherapy: clinical outcomes

  2014cites this paper
• Recent advances in the development of breast cancer vaccines

  2014cites this paper
• A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer

  2014cites this paper
• Mucins and Cancer

  2013cites this paper
• Targeting Antigens to Dendritic Cell Receptors for Vaccine Development

  2013cites this paper
• MUC1 as a therapeutic target in cancer

  2013cites this paper
• Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1.

  2013cites this paper
• The sweet side of tumor immunotherapy.

  2012cites this paper
• Natural and Induced Humoral Responses to MUC1

  2011cites this paper
• Enhanced induction of anti-tumor CTLs in vitro by a lentivirus-transduced dendritic cell vaccine expressing secondary lymphoid tissue chemokine and mucin 1.

  2011cites this paper
• Therapeutic vaccines for gastrointestinal cancers.

  2011cites this paper
• Development and progression of colorectal neoplasia

  2011cites this paper
• The MUC1 oncoprotein as a functional target: Immunotoxin binding to α/β junction mediates cell killing

  2009cites this paper
• Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?

  2009cites this paper
• The RAV12 monoclonal antibody recognizes the N-linked glycotope RAAG12: expression in human normal and tumor tissues.

  2009cites this paper
• Tumor Vaccines for Breast Cancer

  2009cites this paper
• Mannose-targeted systems for the delivery of therapeutics

  2008influential citation
• Strategies used for MUC1 immunotherapy: human clinical studies

  2008cites this paper
• Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo

  2008cites this paper
• Mucin-type O-glycosylation and its potential use in drug and vaccine development.

  2008cites this paper
• Strategies used for MUC1 immunotherapy: preclinical studies

  2008cites this paper
• Protein/peptide and DNA vaccine delivery by targeting C-type lectin receptors

  2008cites this paper
• Dendritic cell mRNA delivery strategies for ovarian cancer immunotherapy

  2007cites this paper
• Mannan‐mediated gene delivery for cancer immunotherapy

  2007cites this paper
• Current immunotherapeutic strategies in colon cancer.

  2007cites this paper
• Receptor-mediated delivery of antigens to dendritic cells: anticancer applications.

  2007cites this paper
• Presented by Dendritic Cells Captured by Multiple Lectin Receptors and Glycoantigens Are Cryptococcus neoformans

  2006cites this paper
• Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]

  2006cites this paper
• Heat shock fusion protein induces both specific and nonspecific anti‐tumor immunity

  2006cites this paper
• Clinical results of vaccine therapy for cancer: learning from history for improving the future.

  2006cites this paper
• MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 alpha/beta junction antibodies that target malignant cells.

  2006cites this paper
• Cryptococcus neoformans Glycoantigens Are Captured by Multiple Lectin Receptors and Presented by Dendritic Cells1

  2006cites this paper
• Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells

  2006cites this paper
• Pathogen recognition and development of particulate vaccines: does size matter?

  2006cites this paper
• Cancer vaccines: preclinical studies and novel strategies.

  2006cites this paper
• [Immunotherapy of colorectal cancer--overview and perspectives].

  2006cites this paper
• Mannan-MUC1–Pulsed Dendritic Cell Immunotherapy: A Phase I Trial in Patients with Adenocarcinoma

  2006cites this paper
• Design of peptide-based vaccines for cancer.

  2006cites this paper
• Immuntherapie des Kolorektalkarzinoms - aktueller Stand und Perspektiven

  2006cites this paper
• MUC1/X Protein Immunization Enhances cDNA Immunization in Generating Anti-MUC1 α/β Junction Antibodies that Target Malignant Cells

  2006cites this paper
• MUC1 as a target antigen for cancer immunotherapy

  2005cites this paper
• Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials

  2005cites this paper
• Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results.

  2005cites this paper
• Immuntherapie gastrointestinaler Tumoren

  2005cites this paper
• Peptide vaccines against cancer.

  2005cites this paper
• Cancer Treatment and Research

  2005cites this paper
• Vaccine Therapy for Breast and Ovarian Cancers

  2004cites this paper
• Colorectal cancer vaccines: principles, results, and perspectives.

  2004cites this paper
• Immunotherapy of surgical malignancies.

  2004cites this paper
• MUC1 immunobiology: from discovery to clinical applications.

  2004cites this paper
• Peptide-based vaccines for cancer immunotherapy

  2004cites this paper
• Mannose receptor-targeted vaccines

  2004cites this paper
• Dendritic cells in tumor immunology and immunotherapy.

  2004cites this paper
• How does the immune system attack cancer

  2004cites this paper
• Peptide-Based Vaccines in Breast Cancer

  2004cites this paper
• Immunology and immunotherapy of colorectal cancer.

  2003cites this paper
• ANTÍGENOS TUMORALES Y DESARROLLO DE VACUNAS

  2003cites this paper
• Vaccines and Immunostimulants

  2003cites this paper
• Ribavirin in cancer immunotherapies: controlling nitric oxide augments cytotoxic lymphocyte function.

  2003cites this paper
• Aspects of cancer immunotherapy

  2003cites this paper
• Ins and outs of clinical trials with peptide-based vaccines.

  2002cites this paper
• Ribavirin in Cancer Immunotherapies Controlling Nitric Oxide Helps Generate Cytotoxic Lymphocyte

  2002cites this paper
• Breast cancer vaccines: current research and future prospects

  2002cites this paper
• Vaccines and gene therapy for colorectal cancer

  2002cites this paper
• The use of carbohydrate antigens for the preparation of vaccines for therapy in breast cancer.

  2002cites this paper
• Breast Cancer in Mice: Effect of Murine Muc-1 Immunization on Tumor Incidence in C3H/HeOuj Mice

  2001cites this paper